sacituzumab govitecan-hziy
AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS
The companies will conduct a Phase III trial of datopotamab deruxtecan following positive results from a Phase I TNBC cohort presented at the meeting.
European Commission Approves Gilead's Trodelvy for Metastatic TNBC
The EC approved Gilead's Trop-2 directed antibody drug conjugate for advanced, pretreated TNBC patients based on the results of the Phase III ASCENT study.
Gilead Sciences Q3 CAR T-Cell Therapy Sales Increase 51 Percent
The firm's overall revenues increased 13 percent to $7.42 billion, driven in part by new autologous CAR T-cell therapy indications.
CHMP Recommends Gilead's Trodelvy for Pretreated TNBC
The committee recommended that sacituzumab govitecan be approved in Europe for metastatic triple-negative breast cancer patients after two or more lines of treatment.
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.